Matt Posted September 24, 2016 Report Share Posted September 24, 2016 I've only just skimmed over the study, not really read through properly, but thought I'd share. :) Two interesting results: 17-α-estradiol "17aE2, previously shown to provide modest and variable improvements in male lifespan, has now been tested at a higher dose, and shown to produce dramatic and consistent improvement in male longevity, but no benefits to female mice. 17aE2 males live 19% longer than control males and longer than control or 17aE2-treated females." And Rapamycin/Met "Although the current (C2011) cohort did not contain any mice given Rapa alone, we thought it would be of interest to compare the survival of mice receiving both Rapa and Met to survival of mice treated with the same Rapa dose in previous years, C2006 and C2009 (Miller et al., 2011, 2014). Results are shown in Table S4 (Supporting information). Males given Met/Rapa had a 23% increase in median longevity, higher than the 10% effect produced by Rapa alone in C2006 or the 13% effect in C2009 males. When the results from C2006 and C2009 males were combined for optimal statistical power, and compared with survival in C2011 mice receiving Met/Rapa, the difference did not reach statistical significance (P = 0.12) using our standard calculation, which stratifies by site. An alternate analysis, omitting site stratification, found P = 0.049 for the contrast between Met/Rapa and the historical datasets using Rapa alone at the same dose. Female mice given Met/Rapa also had a higher percentage increase in median lifespan (23%) than females that had received rapamycin alone in the previous C2006 and C2009 cohorts (18% and 21%, respectively), but the difference did not reach significance by log-rank testing." Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer Aging Cell. 2016 Oct;15(5):872-84. doi: 10.1111/acel.12496. Epub 2016 Jun 16. The National Institute on Aging Interventions Testing Program (ITP) evaluates agents hypothesized to increase healthy lifespan in genetically heterogeneous mice. Each compound is tested in parallel at three sites, and all results are published. We report the effects of lifelong treatment of mice with four agents not previously tested: Protandim, fish oil, ursodeoxycholic acid (UDCA) and metformin – the latter with and without rapamycin, and two drugs previously examined: 17-α-estradiol and nordihydroguaiaretic acid (NDGA), at doses greater and less than used previously. 17-α-estradiol at a threefold higher dose robustly extended both median and maximal lifespan, but still only in males. The male-specific extension of median lifespan by NDGA was replicated at the original dose, and using doses threefold lower and higher. The effects of NDGA were dose dependent and male specific but without an effect on maximal lifespan. Protandim, a mixture of botanical extracts that activate Nrf2, extended median lifespan in males only. Metformin alone, at a dose of 0.1% in the diet, did not significantly extend lifespan. Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit, based on historical comparison with earlier studies of rapamycin given alone. The α-glucosidase inhibitor, acarbose, at a concentration previously tested (1000 ppm), significantly increased median longevity in males and 90th percentile lifespan in both sexes, even when treatment was started at 16 months. Neither fish oil nor UDCA extended lifespan. These results underscore the reproducibility of ITP longevity studies and illustrate the importance of identifying optimal doses in lifespan studies. http://onlinelibrary.wiley.com/doi/10.1111/acel.12496/full Link to comment Share on other sites More sharing options...
mccoy Posted October 3, 2016 Report Share Posted October 3, 2016 The results are interesting indeed, outlining the synergistic effects of rapamycin andmetformin, both molecules alreday known to promote longevity if I don't err. My serious doubts on drugs treatment for human longevity regards the possible side effects, I'm new here and I don't know if this has already been discussed. Maybe as an OT question I'll ad, As far as you guys know, are drugs already being administered to healthy human subjects for the specific purpose to promote longevity? Please advise if my question should be moved to another thread. Link to comment Share on other sites More sharing options...
Gordo Posted October 6, 2016 Report Share Posted October 6, 2016 Big pharma is working on a version of Rapamycin that doesn't also compromise one's immune system or promote cancer, but like you I don't get warm fuzzies about anti-aging drugs. Metformin has a long list of negative side effects including GI tract problems. There are reasons to believe metformin is not an anti-aging drug, but I guess we'll know more soon. I tend to think you can get the (alleged) benefits of any of these current generation drugs though diet (plants) and lifestyle (particularly cold exposure, maybe fasting). These pharmaceuticals aren't offering any value beyond what a disciplined person can achieve without them and are more likely to do more harm than good. Yet I continue to watch the industry in hopes that they do come up with something more promising. Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.